



Points to Consider for the Aseptic Processing of Sterile Pharmaceutical Products in Isolators

Points to Consider for the Aseptic Processing of Sterile Pharmaceutical Products in Isolators

ISBN: 978-1-945584-14-5

© 2020 Parenteral Drug Association, Inc.

All rights reserved.



PDA Points to Consider for the Aseptic Processing of Sterile Pharmaceutical Products in Isolators Task Force

Authors

Guenther Gapp, Gapp Quality GmbH (Chair)

Shelley Preslar, Azzur Group (Chair)

Marcia Cristina Baroni, Eli Lilly and Company

Harold Baseman, Valsource, Inc.

Jette Christensen, Novo Nordisk

Richard Denk, SKAN

Phil DeSantis, DeSantis Consulting Associates

Dawn Downey, PhD, Eli Lilly and Company

Sabina Lancaster, Novartis

Jahanvi Miller, Parenteral Drug Association

Alexandra Staerk, Novartis

Stephen C. Yang, PhD, Merck & Co., Inc.

Table of Contents

1. INTRODUCTION AND SCOPE	1	TOPIC 5: ENVIRONMENTAL MONITORING	22
2. GLOSSARY	2	Q5-1: What should the environmental monitoring frequency be in an isolator?	23
TOPIC 1: ISOLATOR DESIGN	4	Q5-2: Which surfaces should be monitored in an isolator?	25
Q1-1: What should the pressure differential be between the isolator interior and the surrounding area?	5	Q5-3: Should environmental monitoring excursions in isolators be treated differently compared to excursions in conventional filling lines?	26
Q1-2: What are the design considerations for isolator gloves?	6	Q5-4: Should each satellite/transfer isolator be monitored with a full environmental monitoring program similar to the main isolator?	27
Q1-3: How should the isolator be designed to minimize risk posed by interventions?	7	Q5-5: What factors should be taken into consideration when transferring environmental monitoring plates into and out of an isolator?	29
TOPIC 2: PHYSICAL ENVIRONMENT	8	TOPIC 6: MATERIAL TRANSPORT AND LOADING OF ISOLATORS	30
Q2-1: What should the classification of the room surrounding the isolator be?	9	Q6-1: How should indirect product contact surfaces be sterilized or decontaminated?	31
Q2-2: Should the isolator fill zone have unidirectional flow?	10	Q6-2: Should a test for packaging material integrity of load items be carried out with respect to potential for VHP ingress?	35
Q2-3: Should airflow pattern visualization/demonstration be performed in an isolator?	11	Q6-3: What approaches are recommended for transferring stoppers from outside Grade C or D to inside Grade A/ISO 5 — manual or automated rapid transfer system?	36
Q2-4: Should the isolator environment qualification runs (at rest and in operation) include the sample sites established according to ISO 14644-1 or can a reduced sampling plan be followed based on a risk assessment?	12	Q6-4: How should tubs of sterilized syringes or vials be decontaminated and transferred into the isolator?	38
Q2-5: What techniques should be used to identify, track, and evaluate air flow during qualification and maintenance of the isolator?	13	TOPIC 7: CLEANING, DISINFECTION, DECONTAMINATION: CYCLE DEVELOPMENT AND VALIDATION	39
TOPIC 3: PERSONNEL	15	Q7-1: What are the special considerations for cleaning and disinfecting isolator interiors (nonproduct contact surfaces) prior to decontamination?	40
Q3-1: How should personnel be gowned when working in the isolator or the background environment area during aseptic processing?	16	Q7-2: What are the current options for isolator interior decontamination?	43
Q3-2: Should operator gloves be disinfected prior to entering isolators gloves?	17	Q7-3: Should empty isolator mapping of temperature and humidity be performed as part of decontamination qualification studies?	45
TOPIC 4: INTEGRITY TESTING OF ISOLATOR AND GLOVES	18	Q7-4: What conditions and configurations should be considered during decontamination cycle development and validation?	46
Q4-1: What methods should be used for integrity testing of isolators and gloves?	19		
Q4-2: What should the maintenance program be for gloves?	20		
Q4-3: What is the response to a glove integrity failure?	21		

Q7-5: What are the key differences between cycle development and cycle qualification?	47
Q7-6: Which BI should be used for cycle development and cycle qualification? What are the requirements for such a BI (e.g., spore count, D-value)?	49
Q7-7: How should multiple BIs be used and evaluated during VHP decontamination cycle development and validation?	51
Q7-8: What effect could oil-based HEPA-filter integrity agents have on the isolator decontamination cycle?	53
Q7-9: Should each load be qualified during the decontamination cycle qualification?	54

TOPIC 8: ASEPTIC PROCESS SIMULATIONS (APS)..... 55

Q8-1: What are the special considerations for media fills in isolators?	56
Q8-2: What are the special considerations for isolator APS study acceptance criteria?	57
Q8-3: What are the special considerations and criteria for determining the types and frequency of interventions to be included in isolator APS?	58
Q8-4: Should the connection, use, and unloading of transfer devices, such as RTP containers, DPTE bags, or alpha-beta ports and bags be included in the APS?	60
Q8-5: Should participation in an APS be used to qualify aseptic filling operators working in isolators?	61
Q8-6: Does qualification by participating in an APS on a conventional aseptic processing filling line qualify aseptic processing personnel on a similar isolator filling line?	62
Q8-7: Should the maximum number of operators be considered during the performance of the APS in the isolator?	63

Q8-8: Should the APS be used to validate the isolator loading pattern?	64
Q8-9: What are the special considerations for setting the duration of the APS for multiple shifts and multiple-day campaign production in isolators?	65
Q8-10: What are the special considerations for the inclusion and rejection of units during the isolator APS?	67
Q8-11: Should power failures that result in loss of airflow, loss of differential pressure, or loss of integrity of the isolator be simulated in an APS?	68
Q8-12: What are the special considerations for determining worst-case conditions in an isolator APS?	69

TOPIC 9: BEST PRACTICES IN ASEPTIC OPERATIONS.. 70

Q9-1: Is it necessary to use the same aseptic technique and practices when performing interventions in isolators and conventional fill lines?	71
Q9-2: Should interventions that disrupt unidirectional airflow in the isolator in proximity to or above exposed sterile product, product contact surfaces, and indirect product contact surfaces be permitted?	72
Q9-3: Should contact between decontaminated isolator gloves and direct or indirect product contact surfaces during setup or operations be permitted?	74
Q9-4: Should surfaces or materials that have not been sterilized or decontaminated be exposed in the isolator interior during aseptic operations?	75
Q9-5: Should different precautions or steps be taken when handling decontaminated materials versus sterilized materials in the decontaminated isolator?	76



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org